Media coverage about Enzo Biochem (NYSE:ENZ) has trended somewhat positive on Saturday, according to Accern Sentiment. Accern scores the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Enzo Biochem earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned news coverage about the medical research company an impact score of 47.0717458860194 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

These are some of the media stories that may have impacted Accern’s scoring:

Shares of Enzo Biochem (NYSE ENZ) traded down 1.60% on Friday, hitting $10.47. 299,788 shares of the company traded hands. The company’s market capitalization is $487.35 million. Enzo Biochem has a 12 month low of $4.88 and a 12 month high of $12.04. The stock’s 50-day moving average price is $11.08 and its 200-day moving average price is $9.80.

ENZ has been the topic of several recent research reports. BidaskClub upgraded shares of Enzo Biochem from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, July 19th. Zacks Investment Research upgraded shares of Enzo Biochem from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a research report on Tuesday, June 20th.

ILLEGAL ACTIVITY NOTICE: This piece was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/09/30/enzo-biochem-enz-getting-somewhat-favorable-press-coverage-report-finds.html.

About Enzo Biochem

Enzo Biochem, Inc is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company’s segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies.

Insider Buying and Selling by Quarter for Enzo Biochem (NYSE:ENZ)

Receive News & Stock Ratings for Enzo Biochem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem Inc. and related stocks with our FREE daily email newsletter.